Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery
- 5 February 2025
- journal article
- review article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 46 (6) , 1495-1510
Abstract
The medicinal and recreational uses of Cannabis sativa have been recognized for thousands of years. Today, cannabis-derived medicines are used to treat a variety of conditions, including chronic pain, epilepsy, multiple sclerosis, and chemotherapy-induced nausea. However, cannabis use disorder (CUD) has become the third most prevalent substance use disorder globally. Cannabinoid receptors are the primary targets that mediate the effects of cannabis and its analogs. Despite their importance, the mechanisms of modulation and the full therapeutic potential of cannabinoid receptors remain unclear, hindering the development of the next generation of cannabinoid-based drugs. This review summarizes the discovery and medicinal potential of phytocannabinoids and explores the distribution, signaling pathways, and functional roles of cannabinoid receptors. It also discusses classical cannabinoid drugs, as well as agonists, antagonists, and inverse agonists, which serve as key therapeutic agents. Recent advancements in the development of allosteric drugs are highlighted, with a focus on positive and negative allosteric modulators (PAMs and NAMs) that target CB1 and CB2 receptors. The identification of multiple allosteric sites on the CB1 receptor and the structural basis for allosteric modulation are emphasized, along with the structure-based discovery of ago-BAMs for CB1. This review concludes by examining the future potential of allosteric modulators in cannabinoid drug development, noting that ongoing progress in cannabinoid-derived drugs continues to open new avenues for therapeutic use and paves the way for future research into their full medicinal potential.Keywords
This publication has 193 references indexed in Scilit:
- Fenofibrate Recognition and Gq Protein Coupling Mechanisms of the Human Cannabinoid Receptor CB1Advanced Science, 2024
- Novel cannabinoid receptor 1 inverse agonist CRB‐913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet‐induced obesity mouse modelObesity, 2023
- Multiple Binding Sites Contribute to the Mechanism of Mixed Agonistic and Positive Allosteric Modulators of the Cannabinoid CB1 ReceptorAngewandte Chemie International Edition, 2018
- Behavioral effects of the cannabinoid CB1receptor allosteric modulator ORG27569 in ratsPharmacology Research & Perspectives, 2014
- The P harmacologic and C linical E ffects of M edical C annabisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- The Role of GPR55 in Cancer2012
- Fatty Acid Binding Receptors and Their Physiological Role in Type 2 DiabetesArchiv der Pharmazie, 2008
- Biosynthetic Pathways of the Endocannabinoid AnandamideChemistry & Biodiversity, 2007
- Structural Requirements for Cannabinoid Receptor Probes2005
- Cloning and Chromosomal Localization of a Gene (GPR18) Encoding a Novel Seven Transmembrane Receptor Highly Expressed in Spleen and TestisGenomics, 1997